Company
Headquarters: Zürich, Switzerland
Employees: 6
CEO: Dr. Christoph Antz
€206.3 Million
EUR as of Feb. 1, 2022
US$233.3 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Xlife Sciences AG focuses on the development of life sciences technologies. The company's projects and pipeline include biotech/therapies and technology platforms for antibody therapy, including obesity, acute myeloid leukemia, and acute lymphocytic leukemia; nanovesikel therapy comprising arthritis, MS, and ALS; painkiller solution; screening technology of antibodies; and modification of antibodies and breakdown of polygeny (genetics). Its projects and pipeline also include medical technology and artificial intelligence comprising 3D bioprinting for life; medical technology comprising reprocessing of instruments of surgical robots; medical devices for the early detection of dementia and Parkinson's disease; development of bile duct implants; and analysis software (AI) for the diagnosis/evaluation of X-ray and MRI images for early detection of prostate cancer. The company is headquartered in Zurich, Switzerland.
Top 1-year algo backtest: +287.69%
$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Xlife Sciences AG has the following listings and related stock indices.
Stock: FSX: XLS wb_incandescent
Stock: Munich: XLS wb_incandescent
Stock: XETR: XLS wb_incandescent